5,338
Views
3
CrossRef citations to date
0
Altmetric
Report

Immunogenicity risk assessment for biotherapeutics through in vitro detection of CD134 and CD137 on T helper cells

, , , , ORCID Icon & ORCID Icon
Article: 1898831 | Received 11 Dec 2020, Accepted 01 Mar 2021, Published online: 17 Mar 2021

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (1)

Yoshiyuki Arata, Shigeki Motoyama, Mariko Yano, Tatsuya Ikuno, Shunsuke Ito, Tomochika Matsushita, Akira Takeiri, Yukari Nishito, Nami Yabuki, Hideaki Mizuno, Zenjiro Sampei, Masayuki Mishima, Masaki Honda, Jumpei Kiyokawa, Hiromi Suzuki, Shuichi Chiba, Mitsuyasu Tabo & Chiyomi Kubo. (2023) Rapid in vitro assessment of the immunogenicity potential of engineered antibody therapeutics through detection of CD4+ T cell interleukin-2 secretion. mAbs 15:1.
Read now

Articles from other publishers (2)

Seth G. Thacker, Cheng Her, Logan Kelley-Baker, Derek D C. Ireland, Mohanraj Manangeeswaran, Eric S. Pang & Daniela Verthelyi. (2022) Detection of innate immune response modulating impurities (IIRMI) in therapeutic peptides and proteins: Impact of excipients. Frontiers in Immunology 13.
Crossref
Sivan Cohen & Shan Chung. (2021) In vitro immunogenicity prediction: bridging between innate and adaptive immunity . Bioanalysis 13:13, pages 1071-1081.
Crossref